Full Text View
Tabular View
No Study Results Posted
Related Studies
Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma
This study has been completed.
Study NCT00755976   Information provided by ICORG- All Ireland Cooperative Oncology Research Group

First Received on September 13, 2008.   Last Updated on October 18, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma (Skin)
Additional conditions recognized in this trial
Melanoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
epirubicin hydrochloride
sulindac
immunologic technique
Additional drug interventions recognized in this trial
Epirubicin
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antibiotics, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
ICORG- All Ireland Cooperative Oncology Research Group


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services